In September 2024, the Australian Government published the final report of the Health Technology Assessment (HTA) Policy and Methods Review. On the surface, it is a national reform document. In …
#digitalmarketing
-
-
Early Value Assessments are not shortcuts to reimbursement. They are tests of whether a technology deserves the NHS’s attention while uncertainty is still unresolved. In recent years, NICE has been …
-
What Medicare’s DMHT Codes Signal for Digital Therapeutics Reimbursement and Why Healthcare Is Paying Attention Digital therapeutics reimbursement refers to how public and private healthcare systems pay for evidence-based software …
-
How Reimbursement Actually Works in Poland This paper explains how reimbursement in Poland actually works for MedTech, IVD, digital health, and AI technologies — including the role of NFZ, DRGs …
-
Belgium’s DRG debate is often framed as a shift toward “case-based payment.” That description is technically correct but strategically misleading. In Belgium, DRGs are not a market-shaping instrument; they are …
-
Germany rarely announces a reimbursement change with fanfare. It tends to arrive indirectly through regulation, measurement, and administrative architecture. Sepsis is the latest example. From 1 January 2026, sepsis care …
-
Why “SaMD” Is the Wrong Place to Start On paper, Software as a Medical Device (SaMD) looks like progress.It gives artificial intelligence in healthcare a name, a definition, and a …
-
The HAS / CNEDiMTS route explained science, law, and real-world decisions France operates one of the most structured and evidence-based reimbursement systems for medical devices in Europe. Access is not …
-
MedTech / IVD VC Funding: the investor is modelling reimbursement physics, not admiring your science Most founders pitch MedTech as if capital is attracted by novelty. In regulated healthcare, the …
-
How to Use German NUB Reimbursement Without Getting Trapped After nearly two decades of operational data, one conclusion is unavoidable: German NUB reimbursement is not a neutral innovation gateway. It …